Skip to search formSkip to main contentSkip to account menu

ganetespib

Known as: 3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methylindol-5-yl)-5-hydroxy-4h-1,2,4-triazole 3h-1,2,4-triazol-3-one, 5-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-2,4-dihydro-4-(1-methyl-1h-indol-5-yl)- 
A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Ganetespib binds to and inhibits Hsp90… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

STA 9090

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract P4-14-21: A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive…
Introduction: Targeted therapies in HER2+ MBC significantly improve outcomes but efficacy is limited by therapeutic resistance… 
2015
2015
A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers.
8064 Background: Patients with ALK + non-small cell lung cancer (NSCLC) initially respond to crizotinib, but eventually develop… 
2014
2014
Abstract 1619: Hsp90 inhibitor drug conjugates (HDCs): Construct design and preliminary evaluation
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: Most cytotoxic agents are often broadly active… 
2014
2014
Cell Death and Survival mTOR Inhibition Potentiates HSP 90 Inhibitor Activity via Cessation of HSP Synthesis
Because of their pleiotropic effects on critical oncoproteins, inhibitors of HSP90 represent a promising new class of therapeutic… 
2014
2014
Abstract 5108: The Hsp90 inhibitor ganetespib is a potent chemosensitizer in preclinical colorectal cancer models
Background: More than half of all individuals diagnosed with colorectal cancer (CRC) will develop metastases and require… 
Review
2013
Review
2013
Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or…
Background: Hsp90 is a molecular chaperone protein required for the stabilization and activation of many proteins, referred to as… 
2013
2013
Ganetespib AIDS lung cancer survival.
A randomized phase II clinical trial demonstrated that combining the second-generation heat shock protein 90 inhibitor ganetespib… 
2012
2012
Preclinical Development Targeting KRAS-Mutant Non – Small Cell Lung Cancer with the Hsp 90 Inhibitor Ganetespib
Mutant KRAS is a feature of more than 25% of non–small cell lung cancers (NSCLC) and represents one of the most prevalent… 
2011
2011
P1-17-08: A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC).
Background: Heat shock protein 90 (Hsp90) is a molecular chaperone that maintains the stability of a number of key cellular… 
2011
2011
P3-17-05: Beyond HER2 and Hormonal Agents: The Heat Shock Protein 90 Inhibitor Ganetespib as a Potential New Breast Cancer Therapy.
Background: Ganetespib is a fully synthetic and selective inhibitor of heat shock protein 90 (HSP90), a molecular chaperone…